Table 2.
Anti-TB medications used for the treatment of MDR TB patients in the United States, 2012–2016. (N = 13).
| Drug | Initial regimena | Ever usedb |
|---|---|---|
| First-line medications | ||
| Isoniazid | 0 (0%) | 0 (0%) |
| Rifampin | 2 (15%) | 2 (15%) |
| Rifabutin | 1 (8%) | 2 (15%) |
| Rifapentine | 0 (0%) | 0 (0%) |
| Pyrazinamide | 8 (61.5%) | 8 (61.5%) |
| Ethambutol | 10 (77%) | 10 (77%) |
| Streptomycin | 0 (0%) | 1 (8%) |
| Second-line injectables | ||
| Amikacin | 9 (69%) | 9 (69%) |
| Capreomycin | 4 (31%) | 4 (31%) |
| Fluoroquinolones | ||
| Levofloxacin | 5 (38%) | 5 (38%) |
| Moxifloxacin | 9 (69%) | 10 (77%) |
| Bedaquiline | 0 (0%) | 0 (0%) |
| Clofazimine | 0 (0%) | 0 (0%) |
| Cycloserine | 8 (61.5%) | 9 (69%) |
| Ethionamide | 6 (46%) | 6 (46%) |
| Linezolid | 10 (77%) | 10 (77%) |
| Para-Amino Salicylic Acid | 5 (38%) | 5 (38%) |
MDR = multidrug resistant, i.e., resistant to at least isoniazid and rifampin.
a
Initial regimen indicates any drug initiated within four weeks of the MDR TB treatment start date, and used for a minimum of two weeks.
b
Drugs ever used indicates any drug used at any point after MDR TB treatment start date, and used for a minimum of 2 weeks.